Combination treatment for extensive-stage small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs—lurbinectedin and durvalumab—for people with extensive-stage small cell lung cancer who have already received initial treatment. The goal is to see if this combination can help control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have extensive-stage small cell lung cancer (cancer that has spread beyond one lung).
- You must have completed 4 cycles of standard chemotherapy and at least 3 cycles of durvalumab (an immunotherapy drug).
- You should be physically active and able to take care of yourself (ECOG score 0 or 1).
- Your doctor must expect you to live at least 12 more weeks.
- You must not have cancer that has spread to your brain.
- You must not have had another type of cancer in the past (except for certain non-serious skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, lurbinectedin and serplulimab, as maintenance therapy after initial chemotherapy for people with extensive-stage small cell lung cancer (SCLC) that hasn't spread to the brain. The goal is to see if this approach helps keep the cancer from growing for longer.
This trial tests a combination of durvalumab (immunotherapy) plus radiation and chemotherapy for people with extensive-stage small cell lung cancer that has only a few distant spots. The goal is to see if this approach helps control the cancer better.
This trial is testing a new combination of two drugs (QLC5508 and QL2107) compared to the standard treatment (tislelizumab plus chemotherapy) for people with extensive-stage small cell lung cancer who have not yet received treatment. The goal is to see if the new combination works better at controlling the cancer.
This study tests a new drug (ZL-1310) combined with immunotherapy for people with extensive-stage small cell lung cancer who have not had prior treatment. It compares this new combination to the standard first-line treatment (chemotherapy plus immunotherapy).
This trial studies whether adding palliative (comfort-focused) radiation to the medicine lurbinectedin can better control extensive-stage small cell lung cancer. It may help reduce problems from tumors in places like bones and organs.
This trial tests whether adding lurbinectedin to paclitaxel (a standard chemo drug) helps people with small cell lung cancer that has progressed after prior treatment. You would receive either the combination or paclitaxel alone, and the study compares how well each works.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.